skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

ファーマインテリジェンスはInforma PLCのインフォーマインテリジェンス部門の一部です

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon レポートストア製品ログインProductLogin
Global Search Configuration
  • Close Icon

About Anju

India

+20 year(s) experience

Anju Ghanguarde
Anju is Deputy Asia Editor at Informa’s Scrip & Pink Sheet. She has over two decades of experience in journalism including stints at India's leading financial dailies. Based in Mumbai, India, she covers a range of topics across the pharma and biosimilar landscape. Drug pricing, policy and regulatory affairs, M&A and patents are areas of special interest to her. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.

Anju has extensive experience at India's mainstream financial dailies, The Economic Times, The Hindu Business Line and The Financial Express. As Corporate Bureau Chief (Mumbai), she led a team of reporters at The Financial Express prior to joining Scrip. She’s been associated with Scrip since 2001, when it was part of PJB Publications.

Anju enjoys covering pharma conferences and interviewing industry heads and regulatory/government officials in the region. Occasionally, she also moderates industry panels at key events.

She follows racket sports closely and has previously received recognition at the national level in India. She loves the hills and when not reporting on pharma believes that nature is the best therapy.

Specialties

  • Policy & Regulation
  • Biopharma Pipeline Strategy
  • Biosimilars
  • Biotech
  • Commercial Strategy

Anju Writes For

Analyst Articles